Vendor Intelligence Report: Champion Peptide

Published 3 Jul 2026. 25-page investigative report on who is behind Champion Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 12 Finnrick lab tests, Champion Peptide records 10 pass / 2 fail — an 83% overall pass rate. The tested record is narrow but useful: tirzepatide is the cleaner lane, while retatrutide carries the weaker signal. Current Finnrick coverage is limited to those two GLP-1 products, so the broader advertised catalog should not borrow confidence from them.

CHP is not a one-day storefront. Its GLP-1 Forum sales footprint and named representatives predate the current chppeptide.com domain, but the chronology cuts both ways: the active sales operation arrived before a filing-grade public corporate trail. The vendor’s wording shifted from a Shanghai-named company claim to a broader China-based Champion Biotechnology formulation, with no registry number, legal representative, or business-license record verified in the supplied materials.

The strongest non-lab finding is the brand-cluster evidence. CHP, its US-branded surface, and BCX/Baicaoxiang share infrastructure signals, and a retained CHP footer artifact still refers to Xiang and BCX. That does not prove legal ownership, but it raises real channel-verification risk when paired with crypto-only payment, changing Discord/Telegram/forum contact routes, multiple aliases, and a US-warehouse claim not independently tied to physical stock or current batch COAs.

For buyers, the practical read is directional: CHP looks most defensible only in its tested tirzepatide lane; retatrutide demands tighter batch verification; the broader catalog remains untested by Finnrick here. The full report shows how ratings move under stricter grading and walks through the records needed before sending irreversible crypto.

Inside the full report:

  • Per-product Finnrick breakdown and methodology-divergence charts for retatrutide and tirzepatide
  • Dated operating timeline from GLP-1 Forum launch threads through the current CHP domain
  • Corporate-identity comparison of the Shanghai claim, revised China wording, and missing registry artifacts
  • Infrastructure and brand-cluster analysis covering CHP, championpeptides.us, and BCX/Baicaoxiang
  • US-warehouse, Discord, Telegram, crypto-payment, and COA traceability review
  • Risk matrix separating tirzepatide, retatrutide, broader catalog, and channel-authenticity concerns

Risk assessment

  • Corporate-counterparty opacity risk — high: CHP’s public identity shifted from “Shanghai Champion Biotechnology Co., Ltd” to “We Champion Biotechnology Co. Ltd. from China,” with no registry number, legal representative, PRC filing, or non-pseudonymous officer verified.
  • Multi-brand / official-channel verification risk — high: CHP, championpeptides.us, and BCX/Baicaoxiang share infrastructure/template signals, CHP retained BCX/Xiang footer wording, and no authoritative channel/reseller/anti-counterfeit list was captured.
  • Retatrutide quality-variability risk — medium: Product-specific: retatrutide records 8 Finnrick tests with 6 pass / 2 fail and a 78.27% rating, materially weaker than tirzepatide at 4 pass / 0 fail and 82.68%.
  • Warehouse and COA traceability risk — medium: CHP promotes US warehouse stock, but physical fulfillment and batch linkage were not independently verified; vendor COAs must be live, current, and matched to the vial received.
  • Payment-recourse risk — medium: CHP states that only bitcoin or other cryptocurrencies are accepted and promotes crypto rails, leaving buyers with little practical recourse after transfer.
  • Dispute-resolution and channel-continuity risk — medium: CHP reported Discord platform disruption, and a forum user reported being blocked/muted after questioning an admin testimonial, weakening escalation confidence.
  • High-risk shared-hosting hygiene risk — medium: chppeptide.com sits on a shared InterServer IP with BCX and multiple high-risk illicit-commerce co-tenants; co-tenancy is not affiliation but weakens operational-security and continuity signals.